Baxter International and Halozyme Therapeutics obtained approval from the European Commission to market HyQvia as a replacement treatment for adults with primary and secondary immunodeficiency disorders. The treatment, a combination of human normal immunoglobulin and recombinant human hyaluronidase, is intended to be taken once every three to four weeks.
Baxter/Halozyme's HyQvia wins EU nod for immunodeficiencies
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|